According to Vision Research Reports, the global epileptic seizures treatment market size surpassed at US$ 1.3 Bn in 2019 and to reach US$ 1.7 billion by 2027.
The global epileptic seizures treatment market is expected to grow at a moderate CAGR of 4.1 % over the forecast period 2020 to 2027. Increasing prevalence of epileptic seizures in patients worldwide, focus on providing a seizure-free life to patients, entry of a number of seizure detection devices, advancements in technology, and focus on research and development. Market players should focus on improving the efficacy of existing treatments and improving the accessibility to current epileptic seizures treatments particularly in developing regions.
In epilepsy, the brain activity becomes abnormal, resulting in recurrent seizures that are short episodes of involuntary movement, which may involve a part of the body or the entire body. These seizures in some cases cause loss of consciousness and bladder function, or bowel control. An epileptic seizure is defined as a period of symptoms due to abnormally excessive or synchronous neuronal activity in the brain. Treatment for epileptic seizures include benzodiazepines, phenytoin, and dosphenytoin. Benzodiazepines are first-line treatment for status epilepticus and repetitive seizures due to better efficacy and quicker action.
Drivers
Rise in Prevalence of Epilepsy with Increase in Status Epilepticus & Repetitive Seizures to Drive Global Market
Increase in patient population with status epilepticus and acute repetitive seizures is the major factor fueling the growth of the global epileptic seizures treatment market. According to the World Health Organization (WHO), epilepsy accounts for a considerable proportion of the world’s disease burden; globally, more than 50 million people are affected by this disease. The introduction of novel drug treatments and routes of administration for epileptic seizures and genetic factors associated with brain malformations & epileptic seizures are other factors accelerating the growth of the global epileptic seizures treatment market. Moreover, increase in incidence of cardiovascular diseases, head injuries, brain cancer, infections, and substance abuse drives the global epileptic seizures treatment market.
Diazepam to be Lucrative Segment
In terms of therapeutic, the global epileptic seizures treatment market has been classified into midazolam, alprazolam, diazepam, lorazepam, phenytoin, fosphenytoin, and others. The lorazepam segment dominated the global market in 2019 owing to quick action, long lasting effect, large number of lorazepam prescriptions, and patient preference for oral route. Diazepam is likely to be a promising segment during the forecast period. New route of administration, strategic collaboration between companies for development & commercialization of diazepam, and lower prescription cost for diazepam are the major factors attributed to the higher growth of the diazepam segment.
Status Epilepticus to Dominate Market
Based on type, the global epileptic seizures treatment market has been categorized into repetitive seizures, status epilepticus, and others. The status epilepticus segment accounted for major market share in 2019, owing to rise in number of patients with status epilepticus, pipeline products, new route of administration with better effective ways for the treatment, and rise in awareness about status epilepticus treatment. The status epilepticus segment has been bifurcated into convulsive status epilepticus and non-convulsive status epilepticus.
Nasal to be Preferred Route of Administration
In terms of route of administration, the global epileptic seizures treatment market has been divided into oral/buccal, rectal, nasal, and parenteral. The oral/buccal segment dominated the global epileptic seizures treatment market in 2019. The trend is expected to continue from 2020 to 2030 owing to patient convenience with oral route, approval & launch of buccal film medications, availability of a large number of products that can be administered through oral route, and new products with better patient compliance. Nasal is likely to be a highly lucrative segment during the forecast period. The segment is projected to expand at a higher CAGR during the forecast period due to new drug approval, better penetration among patients due to convenient route, and better tolerability.
Retail Pharmacies to Hold Major Market Share
Based on distribution channel, the global epileptic seizures treatment market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment accounted for major share of the global market in 2019 due to easy availability of branded as well as generic drugs, increase in number of pharmacy retail chain stores, and joint ventures & strategic collaboration partnerships between retail pharmacy giants.
Regional Overview
Competition Landscape
The global epileptic seizures treatment market is fragmented in terms of number of players, with entry of several new players. Key players in the global market include Bausch Health Companies, Inc., GlaxoSmithKline plc., UCB S.A., Pfizer, Inc., Apotex, Inc., Alexza Pharmaceuticals, Inc., Neurelis, Inc., and Veriton Pharma. New product development with new route of administration, mergers, acquisitions & strategic collaborations, distribution tie-ups, and increased research & development expenditure are the major strategies adopted by leading companies in the global epileptic seizures treatment market.
Market Segmentation
By Therapeutic
By Type
By Route of Administration
By Distribution Channel
By Region
Scope of the Report
VRR’s report on the global epileptic seizures treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the overall market revenue of the global epileptic seizures treatment market for the period 2018–2030, considering 2020 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global epileptic seizures treatment market for the forecast period.
The report has been prepared after extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global epileptic seizures treatment market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomena in the global epileptic seizures treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global epileptic seizures treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global epileptic seizures treatment market.
The report delves into the competition landscape of the global epileptic seizures treatment market. Key players operating in the global epileptic seizures treatment market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global epileptic seizures treatment market that have been profiled in this report.
Key Questions Answered in Epileptic Seizures Treatment Market Report
Research Objectives and Research Approach
The comprehensive report on the global epileptic seizures treatment market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, pipeline analysis, disease prevalence in key countries, key industry events, and impact of COVID-19 in global epileptic seizures treatment market have been provided.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into small ones. The entire report comprises an exhaustive collection of graphs and tables appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global epileptic seizures treatment market in terms of therapeutic, type, route of administration, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2030 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global epileptic seizures treatment market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Epileptic Seizures Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Epileptic Seizures Treatment Market Analysis and Forecast, 2018–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Key Industry Events (mergers, acquisitions, collaborations, partnerships, etc.)
5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Epileptic Seizures Treatment Market Analysis and Forecast, by Therapeutics
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapeutics, 2018–2027
6.3.1. Midazolam
6.3.2. Alprazolam
6.3.3. Diazepam
6.3.4. Lorazepam
6.3.5. Phenytoin
6.3.6. Fosphenytoin
6.3.7. Others
6.4. Market Attractiveness Analysis, by Therapeutics
7. Global Epileptic Seizures Treatment Market Analysis and Forecast, by Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Type, 2018–2027
7.3.1. Repetitive Seizures
7.3.2. Status Epilepticus
7.3.2.1. Convulsive Status Epilepticus
7.3.2.2. Non-convulsive Status Epilepticus
7.3.3. Others
7.4. Market Attractiveness Analysis, by Type
8. Global Epileptic Seizures Treatment Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2018–2027
8.3.1. Oral/Buccal
8.3.2. Rectal
8.3.3. Nasal
8.3.4. Parenteral
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Epileptic Seizures Treatment Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2018–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Epileptic Seizures Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Country/Region
11. North America Epileptic Seizures Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapeutics, 2018–2027
11.2.1. Midazolam
11.2.2. Alprazolam
11.2.3. Diazepam
11.2.4. Lorazepam
11.2.5. Phenytoin
11.2.6. Fosphenytoin
11.2.7. Others
11.3. Market Value Forecast, by Type, 2018–2027
11.3.1. Repetitive Seizures
11.3.2. Status Epilepticus
11.3.2.1. Convulsive Status Epilepticus
11.3.2.2. Non-convulsive Status Epilepticus
11.3.3. Others
11.4. Market Value Forecast, by Route of Administration, 2018–2027
11.4.1. Oral/Buccal
11.4.2. Rectal
11.4.3. Nasal
11.4.4. Parenteral
11.5. Market Value Forecast, by Distribution Channel, 2018–2027
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country, 2018–2027
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Therapeutics
11.7.2. By Type
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Epileptic Seizures Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapeutics, 2018–2027
12.2.1. Midazolam
12.2.2. Alprazolam
12.2.3. Diazepam
12.2.4. Lorazepam
12.2.5. Phenytoin
12.2.6. Fosphenytoin
12.2.7. Others
12.3. Market Value Forecast, by Type, 2018–2027
12.3.1. Repetitive Seizures
12.3.2. Status Epilepticus
12.3.2.1. Convulsive Status Epilepticus
12.3.2.2. Non-convulsive Status Epilepticus
12.3.3. Others
12.4. Market Value Forecast, by Route of Administration, 2018–2027
12.4.1. Oral/Buccal
12.4.2. Rectal
12.4.3. Nasal
12.4.4. Parenteral
12.5. Market Value Forecast, by Distribution Channel, 2018–2027
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2018–2027
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Therapeutics
12.7.2. By Type
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Epileptic Seizures Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapeutics, 2018–2027
13.2.1. Midazolam
13.2.2. Alprazolam
13.2.3. Diazepam
13.2.4. Lorazepam
13.2.5. Phenytoin
13.2.6. Fosphenytoin
13.2.7. Others
13.3. Market Value Forecast, by Type, 2018–2027
13.3.1. Repetitive Seizures
13.3.2. Status Epilepticus
13.3.2.1. Convulsive Status Epilepticus
13.3.2.2. Non-convulsive Status Epilepticus
13.3.3. Others
13.4. Market Value Forecast, by Route of Administration, 2018–2027
13.4.1. Oral/Buccal
13.4.2. Rectal
13.4.3. Nasal
13.4.4. Parenteral
13.5. Market Value Forecast, by Distribution Channel, 2018–2027
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2018–2027
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Therapeutics
13.7.2. By Type
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Epileptic Seizures Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapeutics, 2018–2027
14.2.1. Midazolam
14.2.2. Alprazolam
14.2.3. Diazepam
14.2.4. Lorazepam
14.2.5. Phenytoin
14.2.6. Fosphenytoin
14.2.7. Others
14.3. Market Value Forecast, by Type, 2018–2027
14.3.1. Repetitive Seizures
14.3.2. Status Epilepticus
14.3.2.1. Convulsive Status Epilepticus
14.3.2.2. Non-convulsive Status Epilepticus
14.3.3. Others
14.4. Market Value Forecast, by Route of Administration, 2018–2027
14.4.1. Oral/Buccal
14.4.2. Rectal
14.4.3. Nasal
14.4.4. Parenteral
14.5. Market Value Forecast, by Distribution Channel, 2018–2027
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2018–2027
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Therapeutics
14.7.2. By Type
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Epileptic Seizures Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Therapeutics, 2018–2027
15.2.1. Midazolam
15.2.2. Alprazolam
15.2.3. Diazepam
15.2.4. Lorazepam
15.2.5. Phenytoin
15.2.6. Fosphenytoin
15.2.7. Others
15.3. Market Value Forecast, by Type, 2018–2027
15.3.1. Repetitive Seizures
15.3.2. Status Epilepticus
15.3.2.1. Convulsive Status Epilepticus
15.3.2.2. Non-convulsive Status Epilepticus
15.3.3. Others
15.4. Market Value Forecast, by Route of Administration, 2018–2027
15.4.1. Oral/Buccal
15.4.2. Rectal
15.4.3. Nasal
15.4.4. Parenteral
15.5. Market Value Forecast, by Distribution Channel, 2018–2027
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2018–2027
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Therapeutics
15.7.2. By Type
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share/Position Analysis, by Company, 2019
16.3. Competitive Business Strategies
16.4. Company Profiles
16.4.1.Bausch Health Companies, Inc.
16.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.1.2. Company Financials
16.4.1.3. Growth Strategies
16.4.1.4. SWOT Analysis
16.4.2.GlaxoSmithKline plc.
16.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.2.2. Company Financials
16.4.2.3. Growth Strategies
16.4.2.4. SWOT Analysis
16.4.3.UCB S.A.
16.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.3.2. Company Financials
16.4.3.3. Growth Strategies
16.4.3.4. SWOT Analysis
16.4.4. Pfizer, Inc.
16.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.4.2. Company Financials
16.4.4.3. Growth Strategies
16.4.4.4. SWOT Analysis
16.4.5.Apotex, Inc.
16.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.5.2. Company Financials
16.4.5.3. Growth Strategies
16.4.5.4. SWOT Analysis
16.4.6.Alexza Pharmaceuticals, Inc.
16.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.6.2. Company Financials
16.4.6.3. Growth Strategies
16.4.6.4. SWOT Analysis
16.4.7. Neurelis, Inc.
16.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.7.2. Company Financials
16.4.7.3. Growth Strategies
16.4.7.4. SWOT Analysis
16.4.8.Veriton Pharma
16.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.8.2. Company Financials
16.4.8.3. Growth Strategies
16.4.8.4. SWOT Analysis